156 related articles for article (PubMed ID: 8438496)
1. Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.
Kriaa F; Hiesse C; Alard P; Lantz O; Noury J; Charpentier B; Bazin H
Transplant Proc; 1993 Feb; 25(1 Pt 1):817-9. PubMed ID: 8438496
[No Abstract] [Full Text] [Related]
2. Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation.
Carpenter CB; Kirkman RL; Shapiro ME; Milford EL; Tiney NL; Waldmann TA; Zimmerman CE; Ramos EL; Strom TB
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):54-7. PubMed ID: 2683758
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial.
van Gelder T; Zietse R; Yzermans JN; Rischen-Vos J; Vaessen LM; Weimar W
Transplant Proc; 1996 Dec; 28(6):3221-2. PubMed ID: 8962247
[No Abstract] [Full Text] [Related]
4. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
5. The role of a primate model of renal transplantation in the development of new monoclonal antibodies.
Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938
[TBL] [Abstract][Full Text] [Related]
6. [Salvage therapy with anti-IL-2 receptor antibodies in high-risk kidney transplant patients].
Carl S; Wiesel M; Deiss JM; Daniel V; Opelz G; Staehler G
J Urol (Paris); 1997; 103(1-2):7-9. PubMed ID: 9765770
[No Abstract] [Full Text] [Related]
7. Five-years' experience with cadaveric kidney transplantation at King Faisal Specialist Hospital and Research Center, Riyadh.
Lundgren G; Alfurayh O; Duffy BB; Nicholls P; Qunibi W; al-Sabban E; Sanjad S; Taher S
Transplant Proc; 1992 Oct; 24(5):1840. PubMed ID: 1412873
[No Abstract] [Full Text] [Related]
8. Lifespan analysis of 212 transplanted kidney grafts: effects of use of humanized anti-IL-2R monoclonal antibody in graft survival at 1, 3, and 5 years for 108 recipients.
Maciel RF
Transplant Proc; 2007 Oct; 39(8):2507-8. PubMed ID: 17954159
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation.
Hiesse C; Kriaa F; Alard P; Lantz O; Noury J; Bensadoun H; Benoit G; Charpentier B; Fries D; Bazin H
Transpl Int; 1992; 5 Suppl 1():S444-7. PubMed ID: 14621841
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody].
Campana C
Ital Heart J Suppl; 2000 Jun; 1(6):838-9. PubMed ID: 11204021
[No Abstract] [Full Text] [Related]
11. The role of newer monoclonal antibodies in renal transplantation.
Vincenti F
Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
[No Abstract] [Full Text] [Related]
12. CD4 and CD25 monoclonal antibody cocktail in kidney transplant rejection prophylaxis: clinical results of a pilot study.
Mousson C; Tanter Y; Racadot E; Wijdenes J; Chalopin JM; Chevet D; Hervé P; Rifle G
Transplant Proc; 1995 Apr; 27(2):1727-8. PubMed ID: 7725472
[No Abstract] [Full Text] [Related]
13. Is there any role for antithymocyte induction in renal transplantation?
Neidlinger NA; Sollinger HW
Transplant Proc; 2010 Jun; 42(5):1402-7. PubMed ID: 20620444
[TBL] [Abstract][Full Text] [Related]
14. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival.
Tesi RJ; Elkhammas EA; Henry ML; Davies EA; Salazar A; Ferguson RM
Transplant Proc; 1993 Feb; 25(1 Pt 2):901-2. PubMed ID: 8442261
[No Abstract] [Full Text] [Related]
15. Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation.
Beaudreuil S; Durrbach A; Noury J; Ducot B; Kriaa F; Bazin H; Charpentier B
Transpl Int; 2006 Oct; 19(10):814-20. PubMed ID: 16961773
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL
Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic and functional analysis of graft-infiltrating cells following therapy with anti-interleukin-2 receptor monoclonal antibody and cyclosporine A in the rat.
Sido B; Morris PJ; Dallman M
Transplant Proc; 1992 Dec; 24(6):2549-50. PubMed ID: 1465862
[No Abstract] [Full Text] [Related]
18. Effect of monoclonal antibody on corneal graft survival across major and minor histocompatibility mismatches.
Duguid IG; Koulmanda M; Mandel TE
Transplant Proc; 1993 Feb; 25(1 Pt 1):844. PubMed ID: 8438499
[No Abstract] [Full Text] [Related]
19. Single center experience with the CTS-HIT allocation system for highly immunized patients. The Leuven Collaborative Group for Transplantation.
Roels L; Vanrenterghem Y; Waer M; Dendievel J; Emonds MP; Christiaens R; Gruwez J; Michielsen P
Transplant Proc; 1992 Dec; 24(6):2492-3. PubMed ID: 1465841
[No Abstract] [Full Text] [Related]
20. Effect of anti-IL-2-receptor monoclonal antibody BT 563 in treatment of acute interstitial renal rejection.
Carl S; Wiesel M; Daniel V; Staehler G
Transplant Proc; 1995 Feb; 27(1):854-5. PubMed ID: 7879205
[No Abstract] [Full Text] [Related]
[Next] [New Search]
